BR112016004095A2 - administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores - Google Patents

administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores

Info

Publication number
BR112016004095A2
BR112016004095A2 BR112016004095A BR112016004095A BR112016004095A2 BR 112016004095 A2 BR112016004095 A2 BR 112016004095A2 BR 112016004095 A BR112016004095 A BR 112016004095A BR 112016004095 A BR112016004095 A BR 112016004095A BR 112016004095 A2 BR112016004095 A2 BR 112016004095A2
Authority
BR
Brazil
Prior art keywords
quinurenine
administration
tumor therapy
depletion
enzymes
Prior art date
Application number
BR112016004095A
Other languages
English (en)
Inventor
Stone Everett
Georgiou George
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112016004095A2 publication Critical patent/BR112016004095A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y307/00—Hydrolases acting on carbon-carbon bonds (3.7)
    • C12Y307/01—Hydrolases acting on carbon-carbon bonds (3.7) in ketonic substances (3.7.1)
    • C12Y307/01003—Kynureninase (3.7.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

são descritos métodos e composições relacionados com a utilização de uma proteína com atividade de quinureninase. por exemplo, em certos aspectos, pode ser revelada uma quinureninase modifi-cada capaz de empobrecer quinurenina. por outro lado, certos aspectos da invenção fornecem composições e métodos para o tratamento de câncer com depleção de quinurenina usando as proteínas ou os ácidos nucleicos descritos.
BR112016004095A 2013-08-30 2014-08-29 administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores BR112016004095A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361872132P 2013-08-30 2013-08-30
US201461986366P 2014-04-30 2014-04-30
PCT/US2014/053437 WO2015031771A2 (en) 2013-08-30 2014-08-29 Administration of kynurenine depleting enzymes for tumor therapy

Publications (1)

Publication Number Publication Date
BR112016004095A2 true BR112016004095A2 (pt) 2017-10-17

Family

ID=52583559

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016004095A BR112016004095A2 (pt) 2013-08-30 2014-08-29 administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores

Country Status (12)

Country Link
US (5) US9808486B2 (pt)
EP (2) EP3492094A1 (pt)
JP (4) JP6307163B2 (pt)
KR (2) KR102271498B1 (pt)
CN (2) CN113957061A (pt)
AU (1) AU2014312119B2 (pt)
BR (1) BR112016004095A2 (pt)
CA (2) CA3173052A1 (pt)
ES (1) ES2707711T3 (pt)
IL (2) IL244312B (pt)
WO (1) WO2015031771A2 (pt)
ZA (1) ZA201601443B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113957061A (zh) 2013-08-30 2022-01-21 得克萨斯大学体系董事会 用于肿瘤疗法的犬尿氨酸耗竭酶的施用
JP7080053B2 (ja) * 2014-08-29 2022-06-03 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
CA3203273A1 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CA2984624A1 (en) * 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
US11723932B2 (en) 2016-01-11 2023-08-15 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
EP3423483A4 (en) * 2016-03-02 2019-08-21 Board Of Regents Of the University Of Texas System VARIANTS OF HUMAN ENZYME KYNURENINASE HAVING IMPROVED PHARMACOLOGICAL PROPERTIES
ES2939646T3 (es) 2016-10-13 2023-04-25 Juno Therapeutics Inc Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
EP3651782A1 (en) 2017-07-12 2020-05-20 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
WO2019089740A1 (en) * 2017-11-03 2019-05-09 Dana-Farber Cancer Institute, Inc. Biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
EA202092487A1 (ru) 2018-04-16 2021-02-05 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Ферменты кинурениназы человека и их применение
CN110412179A (zh) * 2018-04-26 2019-11-05 缪荣明 一种液相色谱检测颗粒酶a的方法
EP3893923A2 (en) * 2018-12-14 2021-10-20 Autolus Limited Cell
EP4045067A4 (en) * 2019-10-17 2023-11-15 Ikena Oncology, Inc. PEGYLATED KYNURENINASE ENZYMES AND THEIR USES FOR THE TREATMENT OF CANCER
WO2023229024A1 (ja) * 2022-05-27 2023-11-30 富士フイルム株式会社 血液腫瘍の診断を補助する方法、血液腫瘍の診断を行うためのデータを得る方法、及びこれらの方法のためのキット
WO2024085280A1 (ko) * 2022-10-20 2024-04-25 서울대학교 산학협력단 신규한 키뉴레니나제 및 이의 용도

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030194721A1 (en) 2001-09-19 2003-10-16 Incyte Genomics, Inc. Genes expressed in treated foam cells
JP2005516605A (ja) 2002-02-01 2005-06-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 心血管疾患を処置するための方法および組成物
CN1330774C (zh) * 2002-03-01 2007-08-08 国家人类基因组南方研究中心 犬尿氨酸水解酶多态性及其用途
EP2260846B1 (en) 2003-03-27 2018-11-28 Lankenau Institute for Medical Research Novel methods for the treatment of cancer
US20070207158A1 (en) 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
JP2008237022A (ja) 2005-06-30 2008-10-09 Osaka Prefecture 非小細胞肺がんの予防・治療剤および診断薬
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
AU2010301042B2 (en) 2009-10-01 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
ES2754394T3 (es) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
SG190997A1 (en) 2010-12-09 2013-07-31 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012099441A2 (ko) * 2011-01-21 2012-07-26 인제대학교산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물
KR20120085209A (ko) * 2011-01-21 2012-07-31 인제대학교 산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물
CN104023713A (zh) * 2011-09-07 2014-09-03 德国癌症研究中心 用于治疗和/或预防天然ahr配体依赖性癌症的手段和方法
JP6267644B2 (ja) 2011-10-20 2018-01-24 アメリカ合衆国 抗ｃｄ２２キメラ抗原受容体
CN113957061A (zh) 2013-08-30 2022-01-21 得克萨斯大学体系董事会 用于肿瘤疗法的犬尿氨酸耗竭酶的施用
JP7080053B2 (ja) 2014-08-29 2022-06-03 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
EP3423483A4 (en) 2016-03-02 2019-08-21 Board Of Regents Of the University Of Texas System VARIANTS OF HUMAN ENZYME KYNURENINASE HAVING IMPROVED PHARMACOLOGICAL PROPERTIES
JP6912171B2 (ja) * 2016-09-15 2021-07-28 株式会社トプコン 眼科検査装置
EA202092487A1 (ru) 2018-04-16 2021-02-05 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Ферменты кинурениназы человека и их применение

Also Published As

Publication number Publication date
US20150064154A1 (en) 2015-03-05
US11534463B2 (en) 2022-12-27
ES2707711T3 (es) 2019-04-04
US9808486B2 (en) 2017-11-07
JP2022159570A (ja) 2022-10-17
WO2015031771A2 (en) 2015-03-05
EP3038636B1 (en) 2018-11-07
JP6307163B2 (ja) 2018-04-04
US10772913B2 (en) 2020-09-15
AU2014312119A1 (en) 2016-03-17
CN105722522B (zh) 2021-10-19
ZA201601443B (en) 2019-08-28
IL264901B (en) 2019-08-29
CA2922670C (en) 2022-11-29
EP3038636A2 (en) 2016-07-06
CA3173052A1 (en) 2015-03-05
KR20160048971A (ko) 2016-05-04
US20210213059A1 (en) 2021-07-15
CN113957061A (zh) 2022-01-21
US20170056449A1 (en) 2017-03-02
JP2020111611A (ja) 2020-07-27
NZ717492A (en) 2021-10-29
WO2015031771A3 (en) 2015-05-14
JP2016533753A (ja) 2016-11-04
AU2014312119B2 (en) 2019-09-19
IL244312A0 (en) 2016-04-21
KR102271498B1 (ko) 2021-07-05
US20240091258A1 (en) 2024-03-21
US20200054674A1 (en) 2020-02-20
EP3492094A1 (en) 2019-06-05
CN105722522A (zh) 2016-06-29
IL244312B (en) 2019-03-31
EP3038636A4 (en) 2017-04-26
JP7029316B2 (ja) 2022-03-03
JP2018127463A (ja) 2018-08-16
CA2922670A1 (en) 2015-03-05
KR20210082264A (ko) 2021-07-02
KR102442231B1 (ko) 2022-09-13

Similar Documents

Publication Publication Date Title
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
CY1121097T1 (el) Ανθρωπινα αντισωματα κατα toy gfr 3 και μεθοδοι χρησης αυτων
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
BR112016006978A2 (pt) inibidores de tirosina quinase de bruton
BR112017016068A2 (pt) composições para modulação de expressão de c9orf72
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
MX366130B (es) Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
WO2015031726A3 (en) Engineered primate l-methioninase for therapeutic purposes
BR112015012536A2 (pt) tratamento de câncer com inibidores heterocíclicos da glutaminase
EA201591281A1 (ru) Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы
UA113712C2 (xx) Антитіло до fap і способи його застосування
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
BR112014031088A8 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
WO2015009726A3 (en) Medical uses of cd38 agonists
EA201500172A1 (ru) Модифицированные полипептиды фактора х и их применение
MX2016008448A (es) Conjugados de var2csa-farmaco.
CR20120508A (es) PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
EA201591925A1 (ru) Терапевтические композиции и их применение

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]